Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia.

Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R.

Neuropsychopharmacol Rep. 2020 Feb 5. doi: 10.1002/npr2.12098. [Epub ahead of print]

2.

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.

Takase M, Kimura H, Kanahara N, Nakata Y, Iyo M.

J Psychopharmacol. 2020 Jan 21:269881119900982. doi: 10.1177/0269881119900982. [Epub ahead of print]

PMID:
31961236
3.

A Medical Marker for Diagnosis of Methamphetamine Addiction - DNA Methylation of SHATI/NAT8L Promoter Sites from Patient Blood.

Kusui Y, Nishizawa D, Hasegawa J, Uno K, Miyanishi H, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Yamada M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Ikeda K, Nitta A.

Curr Pharm Des. 2020 Jan 9. doi: 10.2174/1381612826666200110111703. [Epub ahead of print]

PMID:
31924153
4.

A preliminary exome sequence in three patients with tardive dystonia.

Kanahara N, Nakata Y, Iyo M.

Psychiatr Genet. 2019 Dec 30. doi: 10.1097/YPG.0000000000000248. [Epub ahead of print]

PMID:
31895084
5.

The Effect of Grandmothers' Presence on the Provision of Multidisciplinary Perinatal Support for Pregnant and Postpartum Women with Psychosocial Problems.

Ogawa M, Hashimoto T, Tanaka M, Tachibana M, Seki R, Sato A, Okayama J, Endo M, Saito N, Sato Y, Watanabe H, Nakazato M, Mori E, Shozu M, Iyo M.

J Multidiscip Healthc. 2019 Dec 11;12:1033-1041. doi: 10.2147/JMDH.S228320. eCollection 2019.

6.

Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.

Higuchi T, Ishigooka J, Iyo M, Hagi K.

Asia Pac Psychiatry. 2020 Mar;12(1):e12377. doi: 10.1111/appy.12377. Epub 2019 Dec 13.

PMID:
31837113
7.

Outcomes of administrative involuntary hospitalization: A national retrospective cohort study in Japan.

Shiina A, Sato A, Iyo M, Fujii C.

World J Psychiatry. 2019 Nov 19;9(7):99-106. doi: 10.5498/wjp.v9.i7.99. eCollection 2019 Nov 19.

8.

Genetic combination risk for schizophrenia.

Oishi K, Niitsu T, Kanahara N, Hashimoto T, Komatsu H, Sasaki T, Takase M, Sato Y, Iyo M.

Schizophr Res. 2019 Aug 30. pii: S0920-9964(19)30376-7. doi: 10.1016/j.schres.2019.08.021. [Epub ahead of print] No abstract available.

PMID:
31477374
9.

Long-Term Effectiveness of Cognitive Therapy for Refractory Social Anxiety Disorder: One-Year Follow-Up of a Randomized Controlled Trial.

Yoshinaga N, Kubota K, Yoshimura K, Takanashi R, Ishida Y, Iyo M, Fukuda T, Shimizu E.

Psychother Psychosom. 2019;88(4):244-246. doi: 10.1159/000500108. Epub 2019 May 23. No abstract available.

10.

Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.

Higuchi T, Ishigooka J, Iyo M, Yeh CB, Ebenezer EG, Liang KY, Lee JS, Lee SY, Lin SK, Yoon BH, Nakamura M, Hagi K, Sato T.

Asia Pac Psychiatry. 2019 Jun;11(2):e12352. doi: 10.1111/appy.12352. Epub 2019 Apr 4.

PMID:
30950208
11.

Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.

Higuchi T, Iyo M, Kwon JS, Chou YH, Chen HK, Chen JY, Chen TT, Huang SY, Lee JS, Saeki Y, Tanaka H, Wang TS, Wu BJ, Katoh T, Ishigouoka J.

Asia Pac Psychiatry. 2019 Sep;11(3):e12354. doi: 10.1111/appy.12354. Epub 2019 Mar 25.

PMID:
30912222
12.

Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.

Kanahara N, Yoshimura K, Nakamura M, Oda Y, Watanabe M, Iyo M.

Int Clin Psychopharmacol. 2019 May;34(3):124-130. doi: 10.1097/YIC.0000000000000257.

PMID:
30870237
13.

Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.

Oishi K, Kanahara N, Takase M, Oda Y, Nakata Y, Niitsu T, Ishikawa M, Sato Y, Iyo M.

PLoS One. 2018 Nov 8;13(11):e0207133. doi: 10.1371/journal.pone.0207133. eCollection 2018.

14.

The recognition and expectations of ex-inpatients of mental health services: A web-based questionnaire survey in Japan.

Shiina A, Ojio Y, Sato A, Sugiyama N, Iyo M, Fujii C.

PLoS One. 2018 Oct 15;13(10):e0197639. doi: 10.1371/journal.pone.0197639. eCollection 2018.

15.

First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort.

Kanahara N, Yamanaka H, Suzuki T, Takase M, Iyo M.

BMC Psychiatry. 2018 Sep 3;18(1):274. doi: 10.1186/s12888-018-1853-1.

16.

Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis.

Kanahara N, Hirabayashi M, Mamada T, Nishimoto M, Iyo M.

Schizophr Res. 2018 Dec;202:398-400. doi: 10.1016/j.schres.2018.06.038. Epub 2018 Jun 21. No abstract available.

PMID:
29937327
17.

White Matter Features Associated With Autistic Traits in Obsessive-Compulsive Disorder.

Kuno M, Hirano Y, Nakagawa A, Asano K, Oshima F, Nagaoka S, Matsumoto K, Masuda Y, Iyo M, Shimizu E.

Front Psychiatry. 2018 May 29;9:216. doi: 10.3389/fpsyt.2018.00216. eCollection 2018.

18.

Psychological Distress Symptoms Associated With Life Events in Patients With Bipolar Disorder: A Cross-Sectional Study.

Sato A, Hashimoto T, Kimura A, Niitsu T, Iyo M.

Front Psychiatry. 2018 May 23;9:200. doi: 10.3389/fpsyt.2018.00200. eCollection 2018.

19.

Identifying improvable employment-related factors in schizophrenia patients.

Hasegawa T, Hashimoto T, Kanahara N, Yamanaka H, Ishige M, Sato Y, Iyo M.

Psychiatry Res. 2018 Aug;266:199-205. doi: 10.1016/j.psychres.2018.05.064. Epub 2018 May 28.

PMID:
29870957
20.

A single-arm pilot study of guided self-help treatment based cognitive behavioral therapy for bulimia nervosa in Japanese clinical settings.

Setsu R, Asano K, Numata N, Tanaka M, Ibuki H, Yamamoto T, Uragami R, Matsumoto J, Hirano Y, Iyo M, Shimizu E, Nakazato M.

BMC Res Notes. 2018 Apr 25;11(1):257. doi: 10.1186/s13104-018-3373-y.

21.

Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia.

Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R.

Int J Neuropsychopharmacol. 2018 Jul 1;21(7):631-639. doi: 10.1093/ijnp/pyy013.

22.

Hospital-based child protection teams that care for parents who abuse or neglect their children recognize the need for multidisciplinary collaborative practice involving perinatal care and mental health professionals: a questionnaire survey conducted in Japan.

Okato A, Hashimoto T, Tanaka M, Tachibana M, Machizawa A, Okayama J, Endo M, Senda M, Saito N, Iyo M.

J Multidiscip Healthc. 2018 Feb 22;11:121-130. doi: 10.2147/JMDH.S155352. eCollection 2018.

23.

Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation.

Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, Maekawa M, Toyoshima M, Ushida Y, Suganuma H, Kida S, Yoshikawa T, Iyo M, Hashimoto K.

Sci Rep. 2018 Feb 1;8(1):2158. doi: 10.1038/s41598-018-20538-3.

24.

Effect of educational intervention on attitudes toward the concept of criminal responsibility.

Shiina A, Niitsu T, Sato A, Omiya S, Nagata T, Tomoto A, Watanabe H, Igarashi Y, Iyo M.

World J Psychiatry. 2017 Dec 22;7(4):197-206. doi: 10.5498/wjp.v7.i4.197. eCollection 2017 Dec 22.

25.

Does cognitive behavioral therapy alter mental defeat and cognitive flexibility in patients with panic disorder?

Nagata S, Seki Y, Shibuya T, Yokoo M, Murata T, Hiramatsu Y, Yamada F, Ibuki H, Minamitani N, Yoshinaga N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Oshiro K, Matsuzawa D, Hirano Y, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.

BMC Res Notes. 2018 Jan 12;11(1):23. doi: 10.1186/s13104-018-3130-2.

26.

rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.

Shirayama Y, Takahashi M, Oda Y, Yoshino K, Sato K, Okubo T, Iyo M.

Brain Imaging Behav. 2019 Feb;13(1):75-86. doi: 10.1007/s11682-017-9803-y.

PMID:
29247294
27.

Group cognitive behavioural therapy with compassion training for depression in a Japanese community: a single-group feasibility study.

Asano K, Koike H, Shinohara Y, Kamimori H, Nakagawa A, Iyo M, Shimizu E.

BMC Res Notes. 2017 Dec 4;10(1):670. doi: 10.1186/s13104-017-3003-0.

28.

Increased Subjective Distaste and Altered Insula Activity to Umami Tastant in Patients with Bulimia Nervosa.

Setsu R, Hirano Y, Tokunaga M, Takahashi T, Numata N, Matsumoto K, Masuda Y, Matsuzawa D, Iyo M, Shimizu E, Nakazato M.

Front Psychiatry. 2017 Sep 25;8:172. doi: 10.3389/fpsyt.2017.00172. eCollection 2017.

29.

Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.

Nakata Y, Kanahara N, Iyo M.

J Psychopharmacol. 2017 Dec;31(12):1511-1518. doi: 10.1177/0269881117728428. Epub 2017 Sep 19. Review.

PMID:
28925317
30.

Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with and without Autism Spectrum Disorder: Gray Matter Differences Associated with Poor Outcome.

Tsuchiyagaito A, Hirano Y, Asano K, Oshima F, Nagaoka S, Takebayashi Y, Matsumoto K, Masuda Y, Iyo M, Shimizu E, Nakagawa A.

Front Psychiatry. 2017 Aug 15;8:143. doi: 10.3389/fpsyt.2017.00143. eCollection 2017.

31.

Feasibility of cognitive remediation therapy for adults with autism spectrum disorders: a single-group pilot study.

Okuda T, Asano K, Numata N, Hirano Y, Yamamoto T, Tanaka M, Matsuzawa D, Shimizu E, Iyo M, Nakazato M.

Neuropsychiatr Dis Treat. 2017 Aug 16;13:2185-2191. doi: 10.2147/NDT.S141555. eCollection 2017.

32.

Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.

Oda Y, Fujita Y, Oishi K, Nakata Y, Takase M, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M.

Psychopharmacology (Berl). 2017 Oct;234(20):3027-3036. doi: 10.1007/s00213-017-4695-5. Epub 2017 Jul 25.

PMID:
28744562
33.

Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.

Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M.

Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. Review.

34.

Differences between British and Japanese perspectives on forensic mental health systems: A preliminary study.

Shiina A, Tomoto A, Omiya S, Sato A, Iyo M, Igarashi Y.

World J Psychiatry. 2017 Mar 22;7(1):8-11. doi: 10.5498/wjp.v7.i1.8. eCollection 2017 Mar 22.

35.

The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.

Takase M, Kanahara N, Oda Y, Niitsu T, Watanabe H, Iyo M.

Schizophr Res. 2017 Dec;190:182-183. doi: 10.1016/j.schres.2017.03.014. Epub 2017 Mar 9. No abstract available.

PMID:
28285026
36.

Erratum to: A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study.

Seki Y, Nagata S, Shibuya T, Yoshinaga N, Yokoo M, Ibuki H, Minamitani N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.

BMC Res Notes. 2017 Feb 6;10(1):86. doi: 10.1186/s13104-017-2398-y. No abstract available.

37.

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report.

Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M.

Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):79-81. doi: 10.9758/cpn.2017.15.1.79.

38.

A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder.

Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanii H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N.

Mol Psychiatry. 2018 Mar;23(3):639-647. doi: 10.1038/mp.2016.259. Epub 2017 Jan 24.

39.

Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.

Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M.

Int Clin Psychopharmacol. 2017 May;32(3):169-173. doi: 10.1097/YIC.0000000000000160.

PMID:
28067751
40.

Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.

Tachibana M, Niitsu T, Watanabe M, Hashimoto T, Kanahara N, Ishikawa M, Iyo M.

Asian J Psychiatr. 2016 Dec;24:28-32. doi: 10.1016/j.ajp.2016.08.014. Epub 2016 Aug 18.

PMID:
27931902
41.

Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders.

Matsumoto J, Hirano Y, Hashimoto K, Ishima T, Kanahara N, Niitsu T, Shiina A, Hashimoto T, Sato Y, Yokote K, Murano S, Kimura H, Hosoda Y, Shimizu E, Iyo M, Nakazato M.

Psychiatry Clin Neurosci. 2017 Feb;71(2):124-134. doi: 10.1111/pcn.12490. Epub 2017 Jan 14.

42.

Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression.

Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H.

Ther Innov Regul Sci. 2016 Nov;50(6):743-750. doi: 10.1177/2168479016648731. Epub 2016 Jul 10.

PMID:
30231732
43.

Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial.

Hashimoto T, Shiina A, Hasegawa T, Kimura H, Oda Y, Niitsu T, Ishikawa M, Tachibana M, Muneoka K, Matsuki S, Nakazato M, Iyo M.

Ann Gen Psychiatry. 2016 Oct 19;15:27. eCollection 2016.

44.

Relationship between symptom dimensions and brain morphology in obsessive-compulsive disorder.

Hirose M, Hirano Y, Nemoto K, Sutoh C, Asano K, Miyata H, Matsumoto J, Nakazato M, Matsumoto K, Masuda Y, Iyo M, Shimizu E, Nakagawa A.

Brain Imaging Behav. 2017 Oct;11(5):1326-1333. doi: 10.1007/s11682-016-9611-9.

PMID:
27730476
45.

A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study.

Seki Y, Nagata S, Shibuya T, Yoshinaga N, Yokoo M, Ibuki H, Minamitani N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.

BMC Res Notes. 2016 Oct 7;9(1):458. Erratum in: BMC Res Notes. 2017 Feb 6;10 (1):86.

46.

Relationship between symptom dimensions and white matter alterations in obsessive-compulsive disorder.

Yagi M, Hirano Y, Nakazato M, Nemoto K, Ishikawa K, Sutoh C, Miyata H, Matsumoto J, Matsumoto K, Masuda Y, Obata T, Iyo M, Shimizu E, Nakagawa A.

Acta Neuropsychiatr. 2017 Jun;29(3):153-163. doi: 10.1017/neu.2016.45. Epub 2016 Sep 13.

PMID:
27620171
47.

Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in Adolescents (TRDIA)' Group.

Sasaki T, Hashimoto K, Oda Y, Ishima T, Yakita M, Kurata T, Kunou M, Takahashi J, Kamata Y, Kimura A, Niitsu T, Komatsu H, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shimizu E, Iyo M.

PLoS One. 2016 Aug 18;11(8):e0160767. doi: 10.1371/journal.pone.0160767. eCollection 2016.

48.

Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.

Kimura H, Kanahara N, Sasaki T, Komatsu N, Ishige M, Muneoka K, Ino H, Yoshimura K, Yamanaka H, Suzuki T, Komatsu H, Watanabe H, Shimizu E, Iyo M.

J Psychopharmacol. 2016 Aug;30(8):795-802. doi: 10.1177/0269881116655978. Epub 2016 Jul 1.

PMID:
27371496
49.

Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial.

Yoshinaga N, Matsuki S, Niitsu T, Sato Y, Tanaka M, Ibuki H, Takanashi R, Ohshiro K, Ohshima F, Asano K, Kobori O, Yoshimura K, Hirano Y, Sawaguchi K, Koshizaka M, Hanaoka H, Nakagawa A, Nakazato M, Iyo M, Shimizu E.

Psychother Psychosom. 2016;85(4):208-17. doi: 10.1159/000444221. Epub 2016 May 27.

50.

A randomized, sham-controlled study of high frequency rTMS for auditory hallucination in schizophrenia.

Kimura H, Kanahara N, Takase M, Yoshida T, Watanabe H, Iyo M.

Psychiatry Res. 2016 Jul 30;241:190-4. doi: 10.1016/j.psychres.2016.04.119. Epub 2016 May 6.

PMID:
27179693

Supplemental Content

Support Center